Document Type: Original Article

Authors

1 Department of genetics,faculty of science,islamic azad university of central tehran branch,Tehran, Iran

2 Department of Genetic, Faculty of Science, Islamic Azad University of Central Tehran Branch, Tehran, Iran

10.33945/SAMI/IJABBR.2019.2.5

Abstract

Background: Cytokeratins (CK) are the largest subgroup of interstitial proteins, and their expression changes during the development of cancer. Cytokeratin (CK-18) is one of the major proteins of the epithelial cell skeleton. The expression potential of the CK-18 gene was studied in this research as a molecular biomarker for the diagnosis of breast cancer in the circulatory system using the Real-Time PCR technique. Methods: Blood samples of breast cancer patients and healthy individuals (as the control group) were collected from the Cancer Institute of Imam Khomeini Hospital, Tehran, Iran and their RNA was extracted. In the next step, the cDNA molecule was synthesized using a reverse transcriptase enzyme (RT), and gene-specific primers were designed and synthesized. Then, the expression of CK-18 tumor marker was evaluated by the real-time PCR technique; finally, the data obtained from the cancer samples and the control group was analyzed by the SPSS software.
Results: CK-18 expression was observed and measured in the patients, serum .In addition, according to the disease grade, the CK-18 expression was different in the patients, serum.
Conclusions: The findings of this research can be used in future studies exploring the mechanism of action of this gene as a suitable target for the treatment of breast cancer.

Keywords

Main Subjects

Alix-Panabieres, C, Vendrell, JP, Slijper, M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K. (2009). Full- length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast cancer Res, 11(3):R39.

Allard, WJ, Matera, J, Miller, MC, Repollet, M, Connelly, MC, Rao, C, Tibbe, AG, Uhr, JW, Terstappen, LW. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res, 10(20):6897-6904.

American cancer society. Prevention and early detection, Tumor Markers. American cancer society 2015; 29.

Baccelli, I, Schneeweiss, A, Reithdorf, S, Stenzinger, A, Schillert, A, Vogel, V, Klein, C, Saini, M, Bauerle, T, Wallwiener, M, Holland-Letz T, Höfner T, Sprick M, Scharpff M, Marmé F, Sinn HP, Pantel K, Weichert W, Trumpp A. (2013). Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol, 31(6):539-544.

Bernard, PS, Wittwer, CT. (2002). Real-Time PCR technology for cancer diagnostics. Clin Chem, 48(8):1178-1185.

 Chu, PG, Weiss, LM. (2002). Keratin expression in human tissues and neoplasms. Histopathology, 40(5):403-439. [PubMed]

 Choy, A, McCulloch, PG. (1993). Detection and enumeration of circulating tumor cells in colorectal cancer. Br J Surg, 80:1490.

Cristofanilli, M, Budd, GT, Ellis, MJ, Stopeck, A, Matera, J, Miller, MC, Reuben JM, Doyle, GV, Allard, WJ, Terstappen, LW, Hayes DF. (2004). Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med, 351:781-791.

DeSantis, CE, Fedewa, SA, Goding Sauer, A, Goding Sauer A, Kramer JL, Smith RA. (2016), Breast cancer statistics, 2015: convergence of incidence rates between black and white women. Ca cancer J Clin, 66(1):31-42.                                                                                                         

Dive, C., Smith RA, Garner E, Ward T, George-Smith SS, Campbell F, Greenhalf W, Ghaneh P, Neoptolemos JP. (2010). Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer, 102(3):577-582.

[Internet] WHO: Geneva, Switzerland. Breast cancer .http://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/

Katapodi, MC, Dodd, MJ, Lee, KA, Facione, NC. (2009). Underestimation of Breast Cancer Risk: Influence on Screening Behavior. Oncol Nurs Forum, 36(3):306-314.

 Makarovskiy, AN, Ackerley, W, Wojcik, L, Halpert, GK, Stein, BS, Carreiro, MP, Hixson, DC. (1997). Application of immunomagnetic beads in combination with RT-PCR for the detection of circulating prostate cancer cells. J Clin Lab Anal, 11(6):346-350.

 Naoe, M, Ogawa, Y, Morita, J, Omori, K, Takeshita, K, Shichijyo, T, Okumura, T, Igarashi, A, Yanaihara, A, Iwamoto, S, Fukagai T, Miyazaki A, Yoshida H. (2007). Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer, 109:1439-1445.

Salehi Nodeh, A, Ghafouri, S, Razavi, S, Mirshafie, SA. (2008). Assessment of TPS tumor marker with ELISA for early detection and monitoring of Breast cancer. Payavard Salamat, 2:84-88.

Schrohl AS, Holten-Andersen M, Sweep F, Schmitt M, Harbeck N, Foekens J, Brünner N. (2003). Tumor markers from laboratory to clinical utility. Mol Cell Proteomics, 2(6):378-387.

Shao, MM, Chan, SK, Yu, AM, Lam, CC, Tsang JY, Lui PC, Law BK, Tan PH, Tse GM. (2012). Keratin expression in breast cancers. Virchows Arch, 461(3):313-322.

Siegel, R., Ma, J, Zou, Z, Jemal, A. (2014). Cancer statistics, 2014. Ca Cancer J Clin, 64(1):9-29. [PubMed]

Siegel, RL, Miller, KD, Jemal, A. (2017). Cancer statistics, 2017, Ca cancer J Clin, 67(1):7-30.

Stevart, BW, Wild, CP. (2014). World Cancer Report, Geneva, Switzerland: WHO press.       

Wolfrum, F, Vogel, I, Fandrich, F, Kalthoff, H. (2005). Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. Langenbecks Arch Surg, 390:430-441.

Zhang, L, Ridgway, LD, Wetzel, MD, Ngo, J, Yin, W, Kumar, D, Goodman, JC, Groves,  MD, Marchetti, D. (2013). The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci. Transl. Med, 5(180):180ra48.